Open AccessWorldwide management of hepatocellular carcinoma during the COVID-19 pandemic
Author(s) -
Riccardo Inchingolo,
Fabrizio Acquafredda,
Michèle Tedeschi,
Letizia Laera,
Giammarco Surico,
A. Surgo,
Alba Fiorentino,
Stavros Spiliοpoulos,
Nicola de’Angelis,
Riccardo Méméo
Publication year - 2021
Publication title -
world journal of gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.427
H-Index - 155
eISSN - 2219-2840
pISSN - 1007-9327
DOI - 10.3748/wjg.v27.i25.3780
Subject(s) - pandemic , hepatocellular carcinoma , covid-19 , medicine , betacoronavirus , coronavirus infections , virology , outbreak , disease , infectious disease (medical specialty)
The coronavirus disease 2019 (COVID-19) pandemic has impacted hospital organization, with the necessity to quickly react to face the pandemic. The management of the oncological patient has been modified by necessity due to different allocation of nurses and doctors, requiring new strategies to guarantee the correct assistance to the patients. Hepatocellular carcinoma, considered as one of the most aggressive types of liver cancer, has also required a different management during this period in order to optimize the management of patients at risk for and with this cancer. The aim of this document is to review recommendations on hepatocellular carcinoma surveillance and management, including surgery, liver transplantation, interventional radiology, oncology, and radiotherapy. Publications and guidelines from the main scientific societies worldwide regarding the management of hepatocellular carcinoma during the COVID-19 pandemic were reviewed.